Population model successfully developed to characterize BI-1910 pharmacokinetics and pharmacodynamics across a broad range of ...

Multiple myeloma is considered incurable, but a third of patients in a Johnson & Johnson clinical trial have lived without ...

Morningstar brands and products Company Portfolio ...

Study examines treatment options for those with operable non-small cell lung cancer, the leading cause of cancer deaths ...

In a small study, a third of the participants with multiple myeloma, a common blood cancer which has up until now been deemed incurable, seem to have had their cancer disappear, The New York Times ...

today announced that a poster was presented over the weekend at the 39 th Annual Meeting of the Society for Immunotherapy of Cancer. The conference took place at the George R. Brown Convention ...

Results from a Phase III clinical trial published in the New England Journal of Medicine, show that patients with lung cancer ...

Head and neck cancer patients went disease-free for five years, compared to half that time for people undergoing standard ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...

today announced that two posters will be presented at the upcoming Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting, taking place November 6-10, 2024, in Houston, Texas.

As part of a $93 million grant package, the Cancer Prevention and Research Institute of Texas, known for funding ...

Society for Immunotherapy of Cancer (SITC) 2023 poster. 3 Paston, et al (2024). A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced ...